Could a pill ease lewy body dementia? small trial tests safety

NCT ID NCT06815965

Completed Disease control Sponsor: EIP Pharma Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 4 times

Summary

This completed Phase 2a study tested an oral drug called neflamapimod in 26 people with dementia with Lewy bodies. The main goal was to check safety and how the drug moves through the body over 24 weeks. Researchers also looked at changes in thinking and memory as a secondary measure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: neflamapimod (also called VX-745), a drug taken orally as a capsule
What this could lead to: If successful, this could point toward a treatment that slows or improves symptoms of dementia with Lewy bodies.
What could go wrong: This is a small, early-phase trial focused on safety, not effectiveness. The drug may not work or could have side effects like liver enzyme elevations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES (DLB) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dementia Lewy body dementia Lewy Body Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEMENTIA WITH LEWY BODIES (DLB)

Contacts and locations

Locations

Hôpital Lariboisière - APHP; Centre de Neurologie Cognitive

Paris, 75010, France
Strasbourg University Hospital (Les Hopitaux Universitaires de Strasbourg)

Strasbourg, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.